[A study on hemolysis in hemodialysis patients]

Area of Science:

• Hematology
• Nephrology
• Biochemistry

Context:

• Chronic renal failure (CRF) patients undergoing hemodialysis (HD) often exhibit hemolysis.
• The pathogenesis of this hemolysis is not fully understood, particularly concerning red blood cell fragility.

Purpose:

• To investigate the pathogenesis of hemolysis in CRF patients on HD.
• To evaluate the impact of recombinant human erythropoietin (r-HuEPO) therapy and bicarbonate levels on red cell life span and hemolysis starting point (HSP).

Summary:

• Red cell life span was significantly shorter in HD patients (22.0 days) compared to healthy subjects, improving to 28.1 days post-r-HuEPO therapy.
• Hemolysis starting point (HSP) was elevated in HD patients (106.7 mOsm) and improved with r-HuEPO therapy (101.0 mOsm) and bicarbonate correction (100.8 mOsm).
• HSP showed a negative correlation with plasma bicarbonate levels, suggesting decreased bicarbonate increases osmotic fragility and hemolysis.

Impact:

• These findings indicate that reduced plasma bicarbonate levels contribute to increased red blood cell osmotic fragility and hemolysis in HD patients.
• Therapeutic strategies aimed at correcting bicarbonate levels may mitigate hemolysis and improve red cell survival in this population.
• Understanding these mechanisms can guide better management of anemia and related complications in chronic kidney disease.